Overview
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Current Appointments & Affiliations
Stewart, Hughes and Wendt Distinguished Professor
·
2023 - Present
Neurology, Neuromuscular Disease,
Neurology
Professor of Neurology
·
2018 - Present
Neurology, Neuromuscular Disease,
Neurology
Faculty Network Member of the Duke Institute for Brain Sciences
·
2011 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Associate of the Duke Initiative for Science & Society
·
2017 - Present
Duke Science & Society,
University Initiatives & Academic Support Units
Recent Publications
Author Response: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.
Journal Article Neurology · November 11, 2025 Full text Link to item CiteALSUntangled #80: ISRIB (Integrated stress response InhiBitor).
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · November 2025 ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we assess ISRIB, a molecule that attenuates the integrated stress response (ISR). The ISR is an intracellular signaling network thro ... Full text Link to item CiteExamining IGFBP7 as a potential therapeutic target in people with ALS.
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · September 13, 2025 A single nucleotide variant in an insulin-like growth factor (IGFBP7) promotor, which reduces IGFBP7 levels in brain, was previously associated with an ALS "reversal" phenotype. This raises the question of whether IGFBP7 might be a therapeutic target in AL ... Full text Link to item CiteRecent Grants
SEA-NOBI-ALS
Clinical TrialPrincipal Investigator · Awarded by WideTrial, Inc. · 2025 - 2028Pridopine EAP 2 (Clinical Site Agreement)
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2024 - 2027An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis
ResearchPrincipal Investigator · Awarded by Clene Nanomedicine Inc. · 2024 - 2026View All Grants
Education, Training & Certifications
University of Connecticut ·
1995
M.D.
University of Connecticut ·
1995
Ph.D.